Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria

被引:51
作者
Zechmeister, Ingrid [1 ]
de Blasio, Birgitte Freiesleben [2 ]
Garnett, Geoff [3 ]
Neilson, Aileen Rae [4 ]
Siebert, Uwe [5 ,6 ,7 ,8 ]
机构
[1] Ludwig Boltzmann Inst Hlth Technol Assessment, A-1090 Vienna, Austria
[2] Univ Oslo, Inst Basic Med Sci, Oslo, Norway
[3] Univ London Imperial Coll Sci Technol & Med, Inst Microparasite Epidemiol, London, England
[4] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway
[5] Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Med Decis Making & HTA, Hall In Tirol, LT, Austria
[6] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Decis Sci, Boston, MA 02115 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA
[8] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA
关键词
HPV-vaccination; Cost-effectiveness; Cervical cancer screening; ECONOMIC-EVALUATION; HPV VACCINATION; NATURAL-HISTORY; MODEL; TRANSFERABILITY; INFECTION; HEALTH; IMPACT; WOMEN;
D O I
10.1016/j.vaccine.2009.06.039
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The study predicts long-term cervical cancer related population health and economic effects of introducing the HPV-vaccination for 12-year-old girls (and boys) in addition to current screening compared with screening only. Method: Health effects are predicted by a dynamic transmission model. Model results are used to calculate incremental cost-effectiveness ratios (ICER) in (sic) per life year gained (LYG) for a time-horizon between 2008 and 2060 from a public payer and a societal perspective. Results: Vaccination of girls results a discounted ICER of (sic) 64,000/LYG and (sic) 50,000/LYG from a payer's and societal perspectives respectively. The additional vaccination of boys increases the ICER to (sic) 311,000 and (sic) 299,000/LYG respectively. Results were most sensitive to vaccination price, discount rate and time-horizon. Conclusion: HPV-vaccination for girls should be cost-effective when adopting a longer time-horizon and a societal perspective. Applying a shorter time frame and a payer's perspective or vaccinating boys may not be cost-effective without reducing the vaccine price. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5133 / 5141
页数:9
相关论文
共 50 条
  • [31] Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan
    Connelly, Luke B.
    Le, Ha N. D.
    SEXUAL HEALTH, 2015, 12 (06) : 520 - 531
  • [32] Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore
    Phua, Lee Cheng
    Choi, Horace C. W.
    Wu, Joseph
    Jit, Mark
    Low, Jeffrey
    Ng, Kwong
    Pearce, Fiona
    Hall, Cameron
    Aziz, Mohamed Ismail Abdul
    VACCINE, 2021, 39 (16) : 2262 - 2270
  • [33] Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark
    Olsen, Jens
    Jepsen, Martin Rudbeck
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2010, 26 (02) : 183 - 191
  • [34] The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa
    Sinanovic, Edina
    Moodley, Jennifer
    Barone, Mark A.
    Mall, Sumaya
    Cleary, Susan
    Harries, Jane
    VACCINE, 2009, 27 (44) : 6196 - 6202
  • [35] Cost-effectiveness of using human papillomavirus cancer screening
    Vijayaraghavan, Arthi
    Efrusy, Molly B.
    Goodman, Karyn A.
    Santas, Christopher C.
    Huh, Warner K.
    GYNECOLOGIC ONCOLOGY, 2010, 119 (02) : 237 - 242
  • [36] Online Cost-Effectiveness ANalysis (OCEAN): a user-friendly interface to conduct cost-effectiveness analyses for cervical cancer
    Morina, David
    Marti, Jose Ignacio
    Puig, Pedro
    Diaz, Mireia
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2020, 20 (01)
  • [37] Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore
    Tay, Sun Kuie
    Lee, Bee-Wah
    Sohn, Woo Yun
    Lee, I-Heng
    Mathur, Gaurav
    Sanicas, Melvin
    Van Kriekinge, Georges
    SINGAPORE MEDICAL JOURNAL, 2018, 59 (07) : 370 - 382
  • [38] Cost-effectiveness of Chlamydia Vaccination Programs for Young Women
    Owusu-Edusei, Kwame, Jr.
    Chesson, Harrell W.
    Gift, Thomas L.
    Brunham, Robert C.
    Bolan, Gail
    EMERGING INFECTIOUS DISEASES, 2015, 21 (06) : 960 - 968
  • [39] A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus
    Jiang, Yiling
    Gauthier, Aline
    Postma, Maarten J.
    Ribassin-Majed, Laureen
    Largeron, Nathalie
    Bresse, Xavier
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (11) : 2285 - 2295
  • [40] Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis
    Kulasingam, Shalini L.
    Rajan, Raghu
    Pierre, Yvan St
    Atwood, C. Victoria
    Myers, Evan R.
    Franco, Eduardo L.
    BMC MEDICINE, 2009, 7